DAX
17.743,15 -94,25 (-0,53%) Euro Stoxx 50
4.923,78 -12,79 (-0,26%) Dow Jones 30
37.775,38 +22,07 (+0,06%) Gold
2.395,50 -2,50 (-0,10%) EUR/USD
1,0654 +0,0008 (+0,07%) Bitcoin EUR
60.926,71 +2.091,16 (+3,55%)
Organovo Holdings, Inc. (ONVO)
Vorbörslich:
Organovo Holdings, Inc.
11555 Sorrento Valley Road
Suite 100
San Diego, CA 92121
United States
(858) 224-1000
https://www.organovo.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 18
Leitende Angestellte
| Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
|---|---|---|---|---|
| Mr. Thomas P. Hess CPA, MBA | President & CFO | N/A | N/A | 1964 |
| Dr. Curtis M. Tyree Ph.D. | Senior Vice President of Strategy & Business Development | N/A | N/A | N/A |
Beschreibung
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.
Corporate Governance
Organovo Holdings, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.
